The immunoreactivity of systemic antibodies to Actinobacillus actinomycetemcomitans and Porphyromonas gingivalis in adult periodontitis

European Journal of Oral Sciences

Volumn 113, Issue 3, 2005, Pages 197-202

  Johansson, Anders ^a,c   Buhlin, Kåre ^b   Koski, Riikka ^a   Gustafsson, Anders ^b  

^a UMEÅ UNIVERSITY   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

^c UMEÅ UNIVERSITY   (Sweden)

Author keywords

Actinobacillus actinomycetemcomitans; Cytolethal distending toxin; Immune response; Leukotoxin; Porhyromonas gingivalis

Indexed keywords

BACTERIUM ANTIBODY; EXOTOXIN; LEUKOTOXIN; NEUTRALIZING ANTIBODY; VIRULENCE FACTOR;

ACTINOBACILLUS ACTINOMYCETEMCOMITANS; ADULT; AGED; ARTICLE; BACTERIAL VIRULENCE; BIOASSAY; CONTROLLED STUDY; CORRELATION ANALYSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN CELL; IMMUNOREACTIVITY; MALE; NONHUMAN; PERIODONTITIS; PORPHYROMONAS GINGIVALIS; PREVALENCE;

ACTINOBACILLUS ACTINOMYCETEMCOMITANS; ADULT; AGED; ANTIBODIES, BACTERIAL; BACTERIAL TOXINS; CASE-CONTROL STUDIES; CYTOTOXINS; EXOTOXINS; FEMALE; HUMANS; MALE; MIDDLE AGED; NEUTROPHILS; PERIODONTAL ATTACHMENT LOSS; PERIODONTITIS; PERIODONTIUM; PORPHYROMONAS GINGIVALIS; SEX FACTORS; VIRULENCE FACTORS;

EID: 21144458390     PISSN: 09098836     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-0722.2005.00218.x     Document Type: Article

References (46)

1. PAPAPANOU PN. Periodontal diseases: Epidemiology. Ann Periodontol 1996; 1: 1-36.
2. LOESCHE WJ, SCHORK A, TERPENNING MS, CHEN YM, DOMINGUEZ BL, GROSSMAN N. Assessing the relationship between dental disease and coronary heart disease in elderly U.S. veterans. J Am Dent Assoc 1998; 129: 301-311.
3. GRAU AJ, BECHER H, ZIEGLER CM, LICHY C, BUGGLE F, KAISER C, LUTZ R, BULTMANN S, PREUSCH M, DORFER CE. Periodontal disease as a risk factor for ischemic stroke. Stroke 2004; 35: 496-501.
4. PUSSINEN PJ, JOUSILAHTI P, ALFTHAN G, PALOSUO T, ASIKAINEN S, SALOMAA V. Antibodies to periodontal pathogens are associated with coronary heart disease. Arterioscler Thromb Vasc Biol 2003; 23: 1250-1254.
5. MOMBELLI A. Periodontitis as an infectious disease: specific features and their implications. Oral Dis 2003; 9: 6-10.
6. HARASZTHY VI, ZAMBON JJ, TREVISAN M, ZEID M, GENCO RJ. Identification of periodontal pathogens in atheromatous plaques. J Periodontol 2000; 71: 1554-1560.
7. ROSAN B, LAMONT RJ. Dental plaque formation. Microbes Infect 2000; 2: 1599-1607.
8. SLOTS J. Update on Actinobacillus Actinomycetemcomitans and Porphyromonas gingivalis in human periodontal disease. J Int Acad Periodontol 1999; 1: 121-126.
9. VAN WINKELHOFF AJ, SLOTS J. Actinobacillus actinomycetemcomitans and Porphyromonas gingivalis in nonoral infections. Periodontol 2000, 1999; 20: 122-135.
10. HENDERSON B, NAIR SP, WARD JM, WILSON M. Molecular pathogenicity of the oral opportunistic pathogen Actinobacillus actinomycetemcomitans. Annu Rev Microbiol 2003; 57: 29-55.
11. SLOTS J, TING M. Actinobacillus actinomycetemcomitans and Porphyromonas gingivalis in human periodontal disease: occurrence and treatment. Periodontology 2000 1999; 20: 82-121.
12. ISHIHARA K, NABUCHI A, ITO R, MIYACHI K, KURAMITSU HK, OKUDA K. Correlation between detection rates of periodontopathic bacterial DNA in carotid coronary stenotic artery plaque and in dental plaque samples. J Clin Microbiol 2004; 42: 1313-1315.
13. WELCH RA. RTX toxin structure and function: a story of numerous anomalies and few analogies in toxin biology. Curr Top Microbiol Immunol 2001; 257: 85-111.
14. JOHANSSON A, CLAESSON R, HANSTROM L, SANDSTRÖM G, KALFAS S. Polymorphonuclear leukocyte degranulation induced by leukotoxin from Actinobacillus actinomycetemcomitans. J Periodont Res 2000; 35: 85-92.
15. YAMAGUCHI N, KUBO C, MASUHIRO Y, LALLY ET, KOGA T, HANAZAWA S. Tumor necrosis factor alpha enhances Actinobacillus actinomycetemcomitans leukotoxin-induced HL-60 cell apoptosis by stimulating lymphocyte function-associated antigen 1 expression. Infect Immun 2004; 72: 269-276.
16. KELK P, JOHANSSON A, CLAESSON R, HANSTROM L, KALFAS S. Caspase 1 involvement in human monocyte lysis induced by Actinobacillus actinomycetemcomitans leukotoxin. Infect Immun 2003; 71: 4448-4455.
17. DINARELLO CA. Biologic basis for interleukin-1 in disease. Blood 1996; 87: 2095-2147.
18. DE NARDIN E. The role of inflammatory and immunological mediators in periodontitis and cardiovascular disease. Ann Periodontol 2001; 6: 30-40.
19. DINARELLO CA. Therapeutic strategies to reduce IL-1 activity in treating local and systemic inflammation. Curr Opin Pharmacol 2004; 4: 378-385.
20. SUGAI M, KAWAMOTO T, PERES SY, UENO Y, KOMATSUZAWA H, FUJIWARA T, KURIHARA H, SUGINAKA H, OSWALD E. The cell cycle-specific growth-inhibitory factor produced by Actinobacillus actinomycetemcomitans is a cytolethal distending toxin. Infect Immun 1998; 66: 5008-5019.
21. MAYER MP, BUENO LC, HANSEN EJ, DIRIENZO JM. Identification of a cytolethal distending toxin gene locus and features of a virulence-associated region in Actinobacillus actinomycetemcomitans. Infect Immun 1999; 67: 1227-1237.
22. FABRIS AS, DIRIENZO JM, WIKSTROM M, MAYER MP. Detection of cytolethal distending toxin activity and cdt genes in Actinobacillus actinomycetemcomitans isolates from geographically diverse populations. Oral Microbiol Immunol 2002; 17: 231-238.
23. YAMANO R, OHARA M, NISHIKUBO S, FUJIWARA T, KAWAMOTO T, UENO Y, KOMATSUZAWA H, OKUDA K, KURIHARA H, SUGINAKA H, OSWALD E, TANNE K, SUGAI M. Prevalence of cytolethal distending toxin production in periodontopathogenic bacteria. J Clin Microbiol 2003; 41: 1391-1398.
24. NAKAGAWA T, SAITO A, HOSAKA Y, ISHIHARA K. Gingipains as candidate antigens for Porphyromonas gingivalis vaccine. Keio J Med 2003; 52: 158-162.
25. SUNDQVIST G. Pathogenicity and virulence of black-pigmented gram-negative anaerobes. FEMS Immunol Med Microbiol 1993; 6: 125-137.
26. LAMONT RJ, JENKINSON HF. Life below the gum line: pathogenic mechanisms of Porphyromonas gingivalis. Microbiol Mol Biol Rev 1998; 62: 1244-1263.
27. NYMAN S, LINDHE J. Examination of patients with periodontitis. In: LINDHE J, ed. Clinical Periodontology and Implant Dentistry, 4th edn. Copenhagen: Blackwell Munksgaard, 2003; 403-413.
28. BUHLIN K, GUSTAFSSON A, POCKLEY AG, FROSTEGÅRD J, KLINGE B. Risk factors for cardiovascular disease in patients with periodontitis. Eur Heart J 2003; 24: 2099-2107.
29. JOHANSSON A, HÄNSTROM L, KALFAS S. Inhibition of Actinobacillus actinomycetemcomitans leukotoxicity by bacteria from the subgingival flora. Oral Microbiol Immunol 2000; 15: 218-225.
30. WROBLEWSKI F, LADUE JS. Lactic dehydrogenase activity in blood. Proc Soc Exp Biol Med 1955; 90: 210-213.
31. JOHANSSON A, KALFAS S. Characterization of the proteinase-dependent cytotoxicity of Porphyromonas gingivalis. Eur J Oral Sci 1998; 106: 863-871.
32. BELIBASAKIS G, JOHANSSON A, WANG Y, CLAESSON R, CHEN C, ASIKAINEN S, KALFAS S. Inhibited proliferation of human periodontal ligament cells and gingival fibroblasts by Actinobacillus actinomycetemcomitans: involvement of the cytolethal distending toxin. Eur J Oral Sci 2002; 110: 366-373.
33. WISING C, SVENSSON LA, AHMED HJ, SUNDAEUS V, AHLMAN K, JONSSON IM, MOLNE L, LAGERGARD T. Toxicity and immunogenicity of purified Haemophilus ducreyi cytolethal distending toxin in a rabbit model. Microb Pathog 2002; 33: 49-62.
34. EBERSOLE JL, FREY DE, TAUBMAN MA, SMITH DJ. An ELISA for measuring serum antibodies to Actinobacillus actinomycetemcomitans. J Periodont Res 1980; 1: 621-632.
35. HUNT DE, JONES JV, DOWELL VR JR. A selective medium for isolation of Bacteroides gingivalis. J Clin Microbiol 1985; 23: 441-445.
36. JOHANSSON A, BERGENHOLTZ A, HOLM SE. Strong cytotoxicity to human gingival fibroblasts by Porphyromonas gingivalis ATCC 33277. J Periodont Res 1996; 31: 477-482.
37. PODMORE M, EBERSOLE JL, KINAN EDF. Immunodominant antigens in periodontal disease: a real or illusive concept? Crit Rev Oral Biol Med 2001; 12: 179-185.
38. KINANE DF, MOONEY J, EBERSOLE JL. Humoral immune response to Actinobacillus actinomycetemcomitans and Porphyromonas gingivalis in periodontal disease. Periodontology 2000 1999; 20: 289-340.
39. KINANE DF, LAPPIN DF, KOULOURI O, BUCKLEY A. Humoral immune responses in periodontal disease may have mucosal and systemic immune features. Clin Exp Immunol 1999; 115: 534-541.
40. LAMSTER IB, NOVAK MJ. Host mediators in gingival crevicular fluid, implications for the pathogenesis of periodontal disease. Crit Rev Oral Biol Med 1992; 3: 31-60.
41. LAMSTER IB, KALUSZHNER-SHAPIRA I, HERRERA-ABREU M, SINHA R, GRBIC JT. Serum IgG antibody response to Actinobacillus actinomycetemcomitans and Porphyromonas gingivalis: implications for periodontal diagnosis. J Clin Periodontol 1998; 25: 510-516.
42. MIYAKAWA H, HONMA K, QI M, KURAMITSU HK. Interaction of Porphyromonas gingivalis with low-density lipoproteins: implications for a role for periodontitis in atherosclerosis. J Periodont Res 2004; 39: 1-9.
43. HAUBEK D, DIRIENZO JM, TINOCO EM, WESTERGAARD J, LOPEZ NJ, CHUNG CP, POULSEN K, KILIAN M. Racial tropism of a highly toxic clone of Actinobacillus actinomycetemcomitans associated with juvenile periodontitis. J Clin Microbiol 1997; 35: 3037-3042.
44. HAUBEK D, ENNIBI OK, POULSEN K, BENZARTI N, BAELUM V. The highly leukotoxic JP2 clone of Actinobacillus actinomycetemcomitans and progression of periodontal attachment loss. J Dent Res 2004; 83: 767-770.
45. GROSSI SG, GENCO RJ, MACHTEI EE, HO AW, KOCH G, DUNFORD R, ZAMBON JJ, HAUSMANN E. Assessment of risk for periodontal disease. II. Risk indicators for alveolar bone loss. J Periodontol 1995; 66: 23-29.
46. ORBAK R, ERCIYAS K, KAYA H. Flow-cytometric analysis of T-lymphocyte subsets after different treatment methods in smokers and non-smokers with chronic periodontitis. Int Dent J 2003; 53: 159-164.